Introduction 41
Adenovirus serotype 5 (Ad5) has proven to be one of the most potent in vivo 42 gene delivery vectors for liver-directed gene therapy. As much as 95 to 98% of an 43 intravenously (i.v.) injected dose of Ad5 is trafficked to the liver (12). The adenovirus 44 capsid is comprised of three major proteins: hexon, penton base, and fiber (reviewed in 45 Hexon is the most abundant viral capsid protein with 720 monomers per virion. 53
Hexon organizes into trimers so that three hexon monomers and their loops wrap tightly 54 around each other to create a tower-like structure with a central depression (20, 28) . 55
Each hexon monomer has seven flexible, serotype-specific loops, named hypervariable 56 regions (HVR) (23) that are predicted to be located on the surface of the hexon trimer 57 biotin was purchased from Thermo Scientific and 5 kDa methyl and succinimide 140 heterobifunctional PEG was purchased from Sunbright. Upon use, all PEGs were 141 overlaid with nonreactive nitrogen gas and stored at -20 o C in desiccant. For PEGylation 142 of cysteine-modified vectors, 1 mg PEG was added per 1 x 10 11 vp and rotated at room 143 temp for 1.5 h. After incubation, the virus mixtures were dialyzed at room temperature 144 into degassed and N 2 overlaid 0.5M sucrose/1X KPBS buffer for 2 h, and then in fresh 145 buffer at 4 o C overnight. After dialysis, vector suspensions were injected into mice within 146 3 h. In some cases, genome copies after dialysis were determined by real-time PCR to 147 confirm amounts of virus being injected. were PEGylated. Excess PEG was removed by three sequential buffer exchanges 151 each into 0.5M sucrose buffer using Bio-Spin 30 Tris Columns (Biorad). In 3 wells, 1 x 152 10 9 vp of each virus were bound in a 96-well high-binding ELISA plate. A protein 153 standard of fully biotinylated MBP-AviTag protein (Avidity) was also plated. After 2 h at 154 room temp, the wells were blocked with 3% BSA overnight. Avidin-hrp (1:1000 dilution) 155 was used as a probe for 1 h at room temp. TMB substrate (100 μl/well) was used for 156 detection, followed by 25 μl of 2M sulfuric acid after 15 minutes to stop the reaction. 157
The plate was read at 405nm using a Beckman Coulter DTX 880 Multimode Detector 158
system. An inverse assay to quantify unconjugated cysteines was also used to assess 159 the number of PEGylation events per virion. Cys-modified virus was mock treated or 160
PEGylated at room temp for 1 h. Excess IR800-maleimide (LICOR) was added to each 161 were anesthetized with ketamine/xylazine and injected intraperitoneally (i.p.) with 100 185 µl of D-luciferin (20mg/ml; Molecular Imaging Products) and were imaged on the 186
Lumazone Imaging System (Photometrics, Roper Scientific) for 1-10 min with 1x1 or 187 2x2 binning using no filters or photomultiplication. Lumazone imaging software was 188 used to determine total light intensity per mouse (photons) for data analysis. The Ad5/6 virus mediates 10-fold increases in hepatocyte transduction after i.v. injection 219 (Fig. 1A and (18) ). This effect appeared to be due to reduced interactions of Ad6 HVRs 220 with macrophages and Kupffer cells (18) . 221
Previous data suggests that Ad5 is phagocytosed by Kupffer cells via scavenger 222 receptors (14). Broadly specific scavenger receptors recognize negative charge 223 clusters such as those that are present in Ad HVRs (Fig. 2A) (Table 1) . In contrast, the HVR1 virus had vp/iu 50-fold higher than 253
Ad5. While infectious unit measures were somewhat reduced, the transduction 254 efficiency by the modified viruses was largely unchanged when compared to unmodified 255
Ad5 (Fig. 2C and Table 1). 256
To conditionally block the HVRs, each of the cysteine-modified vectors was 257 reacted with maleimide-activated linear 5 kDa polyethylene glycol (PEG), capped 258 without or with a terminal biotin (for detection). Vectors were suspended in a 0.5 M 259 sucrose buffer to maintain virion activity during these reactions (8) lysines on the surface of the virus and is useful for protecting the virus from pre-existing 287 neutralizing antibodies (9) and reducing side effects (15, 24). While NHS-PEG is potent 288 for shielding, when it is applied under saturating conditions it inactivates the virus in 289
vitro, but not in vivo (10, 24). 290
We hypothesized that targeting PEGylation to specific sites on the virion would 291 only inactivate virus functions specific to that site. Therefore, we predicted that the 292 later by luciferase assay (Fig. 2C) . There was no significant difference in expression 300 between the cysteine-modified vectors and the unmodified control virus with or without 301 PEG modification (Table 1) . To contrast this with NHS-PEGylation, the HVR5 modified 302 virus was non-specifically PEGylated with NHS-PEG or was specifically PEGylated at 303 its targeted cysteine with PEG-maleimide. Consistent with previous results, NHS-PEG 304 reduced transduction more than 100-fold compared to both mock treated and 305 specifically PEGylated adenovirus (Fig. 2D, Fig. 1) . (Fig. 3) . HVRwt control virus mediated robust and similar liver 315 transduction whether mock or treated with PEG. The transduction levels of mock 316
PEGylated cysteine-modified vectors were similar or slightly lower than HVRwt. Viruses 317 that were PEGylated on HVR1, 2, 5, and 7 mediated up to 10-40-fold increases in liver 318 transduction over HVRwt expression (p < 0.01 by one way ANOVA). In contrast, 319
PEGylation of HVR3 and HVR4 mediated smaller increases in transduction that were 320 not statistically-significant. These data suggest that HVR1, 2, 5, and 7 may play a role 321 in virus sequestration in vivo. 322
323

Kupffer cell depletion does not affect transduction by vectors after HVR-targeted 324
PEGylation. Eliminating Kupffer cells by predosing increases liver transduction by 325
unmodified Ad5 10 to 40-fold (18). As found previously with Ad5/6, we hypothesized 326 that HVR PEGylation might reduce uptake of Ad by liver Kupffer cells. If so, PEGylated 327 vectors should be largely unaffected by the presence or absence of liver Kupffer cells. 328
To test this, Kupffer cells were eliminated by predosing mice with irrelevant Ad5-dsRed 329 (Fig. 4A) . HVR3-PEGylated vector transduction was also significantly increased by 332 predosing (p < 0.01). In contrast, predosing did not increase transduction by PEGylated 333 HVR1, 4, or 5 suggesting that Kupffer cell elimination and shielding these HVRs impact 334 the same pathways. To test this, unmodified Ad5 or HVR5 virus were PEGylated with PEG-maleimide 342 and mice were injected i.v. with 30-fold higher doses (3 x 10 11 vp) than before. Under 343 these conditions, increasing the Ad5 dose 30-fold increased liver transduction 10-fold 344 (Fig. 4B) . In contrast, Ad-HVR5 only increased its expression 2.5-fold. These data 345 suggest that PEGylation of HVR5 avoids the threshold effect that normally impacts 346 (Fig. 1A) . 355 HVR1 has the largest number of charged amino acids ( Fig. 2A) demonstrated that the Ad5 hexon is strongly recognized by Kupffer cells and 391 macrophages, whereas Ad5 displaying the Ad6 hexon was not (18). Given that the only 392 molecular differences between Ad5 and Ad5/6 are the HVRs of their hexons, we 393 hypothesized that it was these hypervariable loops that are the key surfaces for 394 interaction with Kupffer cells. We demonstrate here that the Ad5 HVR domain is indeed 395 recognized by the Kupffer cell scavenger receptor SRA-II whereas the Ad6 HVR domain 396 is not. 397
To probe HVR-specific interactions with SRA-II and Kupffer cells, we applied 398 targeted PEGylation to all seven of the Ad5 HVRs using the approach that previously 399 on October 22, 2017 by guest http://jvi.asm.org/ Downloaded from was used to target PEG to HVR5 (11, 27). By this systematic approach, targeted 400
PEGylation of HVR1, 2, 5, and 7 produced marked increases in liver hepatocyte 401 transduction in vivo after intravenous injection. In contrast, PEGylation of HVR3 and 4 402 produced weak effects that did not reach statistical significance. These data implicate 403 HVR1, 2, 5, and 7 as important regions, which are mostly exposed on the virus surface 404 that affect Ad5 pharmacology in vivo. 405
As shown previously with Ad5/6, the increased in vivo transduction by the 406 PEGylated Ads was not further increased by eliminating Kupffer cells prior to injection of 407 these vectors. Nor was it increased by blocking scavenger receptors in vivo with poly 408 (I). These PEGylated vectors also did not suffer the same threshold effect as 409 unmodified Ad5. These data suggest that the in vivo liver transduction increases that 410 were observed for HVR1, 2, 5, and 7 are mediated at least in part by protecting the virus 411 The x-ray structure of the hexon trimer shows that HVRs 1, 2, 5, and 7 (i.e. the 431 four sites at which PEGylation causes >10-fold increased liver expression) are clustered 432 on the surface of the hexon trimer (Fig. 7) . In the context of the entire virion, two 433 regions that may contribute to binding to Kupffer cells are: 1) the depression at the 434 center of each hexon trimer and 2) a depression at the center of three hexon trimers. 435
Given that PEGylation of HVRs 1, 2, 5, and 7 have the strongest effects on Kupffer cell 436 interactions in vivo, that either of these depressions or the rim of either depression may 437 be a binding surface for SRA-II and scavenger receptors. (Fig. 7B) . 438
The binding site of FX has been localized by cryo-electron microscopy and 439 mutagenesis studies to the center depression of the hexon trimer (indicated by a yellow 440 dashed circle, 
